Three Landmark ASCO Studies Yielded Surprising Findings: Does The Wonder Drug Metformin Exert No Anticancer Efficacy?

Jul 06, 2026

Leave a message

Alice Smith
Alice Smith
Alice is a senior R & D scientist at Tianjin Pacific Pharmaceutical Technology Group. With over 10 years of experience in pharmaceutical R & D, she has made significant contributions to the development of new drugs in the group, especially in the area of traditional Chinese medicine preparations.

In recent years, abundant studies have demonstrated that diabetic patients taking metformin hydrochloride exhibit a markedly lower incidence of cancer. Meanwhile, compared with insulin and sulfonylureas for diabetes management, metformin hydrochloride is associated with reduced cancer-specific mortality. For patients with lung cancer, stage IV lung cancer patients complicated with diabetes who receive metformin hydrochloride achieve significantly improved survival rates.

Then, can non-diabetic cancer patients take metformin hydrochloride to delay targeted drug resistance and prolong progression-free survival (PFS) and overall survival (OS)? A host of research data on metformin hydrochloride were presented at this year's ASCO Annual Meeting; let us analyze the trial outcomes in detail.

Metformin Hydrochloride

1. Combination of Metformin Hydrochloride and Gefitinib Fails to Improve PFS or OS in Treatment-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Without Diabetes

 

Preclinical research indicates that metformin hydrochloride can sensitize the anti-tumor efficacy of EGFR-TKIs, yet robust clinical trial validation remains lacking. Against this backdrop, researchers from Daping Hospital conducted a multicenter, double-blind, placebo-controlled phase II clinical trial, whose findings were unveiled at ASCO 2019.

A total of 224 previously untreated stage IIIB/IV NSCLC patients harboring EGFR-sensitizing mutations were enrolled and randomly assigned to two arms: the experimental arm received oral gefitinib 250 mg once daily plus oral metformin hydrochloride 500 mg once weekly, while the control arm received gefitinib combined with placebo. After two weeks, the metformin dosage was titrated up to 1000 mg oral twice daily. The primary endpoint was the 1-year PFS rate; secondary endpoints included PFS, OS, objective response rate (ORR), and safety profiles.

Baseline characteristics were well balanced between the two cohorts. Trial results showed the 1-year PFS rate stood at 41.2% in the experimental arm versus 42.9% in the control arm, with no statistically significant difference (P=0.6268). Addition of metformin hydrochloride yielded no improvements in median PFS (10.3 months vs. 11.4 months), median OS (22.0 months vs. 27.5 months), or ORR (66.0% vs. 66.7%). No survival benefits linked to metformin combination therapy were observed across all subgroup analyses. The incidence of diarrhea was higher in the experimental group (78.38% vs. 43.24%), whereas other adverse events were comparable between arms.

Accordingly, the investigators concluded that concurrent metformin hydrochloride does not improve clinical outcomes for non-diabetic advanced NSCLC patients with EGFR-sensitizing mutations receiving EGFR-TKI therapy.

 

2. Metformin Hydrochloride Combined With Concurrent Chemoradiotherapy Confers No Survival Benefit

 

Led by Professor Theodoros Tsakiridis from Canada's Juravinski Cancer Centre, the phase II NRG-LU001 trial evaluated whether metformin hydrochloride could enhance the efficacy of definitive concurrent chemoradiotherapy in non-diabetic patients with unresectable stage IIIA/IIIB NSCLC.

Between April 2014 and December 2016, 170 eligible patients were randomized in a 1:1 ratio. The control arm received carboplatin plus paclitaxel concurrent with thoracic radiotherapy (60 Gy), followed by consolidation carboplatin-paclitaxel chemotherapy. The experimental arm adopted the identical chemoradiotherapy regimen plus daily metformin hydrochloride 2000 mg throughout chemotherapy cycles.

Trial data revealed 1-year and 2-year PFS rates of 60.4% and 40.1% in the control group, versus 51.3% and 34.5% in the metformin group, with no statistical separation. The 2-year OS rates were nearly identical across cohorts: 65.4% (control) vs. 64.9% (metformin).

Despite acceptable tolerability of metformin when paired with definitive concurrent chemoradiotherapy for locally advanced NSCLC, metformin hydrochloride failed to prolong PFS or OS, nor did it alter rates of local recurrence or distant metastasis.

 

3. Metformin Hydrochloride Delivers No Clinical Benefit to Prostate Cancer Patients

 

The TAXOMET trial, a prospective multicenter randomized phase II study, compared docetaxel plus metformin hydrochloride versus docetaxel plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint was PSA response rate (≥50% PSA reduction); secondary endpoints encompassed ORR, PFS, OS, metformin safety, and quality of life (QoL). Ninety-nine patients were recruited in total. No intergroup disparities were detected: PSA response rate reached 72% and ORR 28% in both arms. The clinical/biological median PFS was 7.3 months (metformin arm) versus 5.8 months (placebo arm, P=0.848), and median OS was 24.2 months vs. 19.7 months (P=0.53). In terms of adverse events, diarrhea showed a numerical trend toward higher frequency in the metformin cohort (70% vs. 50%, P=0.072), with few grade 3–4 episodes reported; all other toxicities were equivalent between groups. QLQ-C30 scores collected during treatment demonstrated no differences in quality of life. The TAXOMET trial confirmed that the addition of metformin hydrochloride produces no tangible clinical benefits for this patient population.

 

Comprehensive Summary & Supplementary Discussion

 

Collectively, the above trials suggest that diabetic cancer patients may benefit from metformin combined with targeted agents, as numerous studies have validated its anti-tumor activity in this population. However, consistent evidence indicates non-diabetic cancer patients cannot derive survival gains from metformin monotherapy or combination regimens.

Notably, although the aforementioned trials negate therapeutic benefits of metformin hydrochloride for non-diabetic cancer patients, extensive research continues to explore its anti-neoplastic mechanisms. For instance, a phase III clinical trial validated certain anti-cancer efficacy of metformin hydrochloride in non-diabetic colorectal cancer patients. Metformin combined with heme suppresses proliferation of triple-negative breast cancer cells; metformin degrades PD-L1 to reverse tumor-mediated immune suppression and boost anti-tumor immune responses.

A recent study conducted at West China School of Stomatology, Sichuan University further discovered that metformin hydrochloride eliminates stem cell properties of head and neck cancer-initiating cells and blocks their malignant transformation.

In conclusion, abundant mechanistic research into metformin's anti-cancer effects has emerged in recent years, yet unified clinical translational conclusions remain elusive. Therefore, clinical medication must prioritize individualized patient management, especially when administering drugs hailed as "miracle drugs."

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!